Abingworth raises Europe’s biggest biotech fund

Abingworth, the UK life sciences VC house, has raised Europe’s largest ever venture fund dedicated to life sciences. Abingworth Bioventures V (ABV V) has €455m at its disposal, well over the target size of €380m.

The fund attracted so much interest the firm decided to limit its capacity to the final total, which it will now invest in biotechnology and medical companies across Europe and the US. It will target companies operating in technologies, therapeutics ...

This content is available for Buyouts subscribers only. Request a free trial to get access for a limited period

If you already have an active Buyouts subscription, please sign in to view this article.

Digital Edition

To read a digital copy of our latest magazine

click here

PE News Briefs